Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLN | Q9BYT8 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | MC3R | P41968 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125544 | 0.84 | NLN (0.50) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL5125551 | 0.84 | NLN (0.50) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL30104067 | 0.82 | OPRD1 (0.54) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL5556817 | 0.82 | NLN (0.62) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL6019536 | 0.80 | CTSS (0.61) | NLNDPP4OPRD1HTR2AHTR2C | |
| SCHEMBL5558741 | 0.80 | CA12 (0.52) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL1769595 | 0.79 | NLN (0.50) | NLNDPP4OPRD1HTR2AHTR2C | |
| SCHEMBL1769590 | 0.79 | NLN (0.50) | NLNDPP4OPRD1HTR2AHTR2C | |
| SCHEMBL12520303 | 0.79 | NLN (0.50) | NLNDPP4OPRD1HTR2AHTR2C | |
| SCHEMBL24455558 | 0.78 | CSK (0.55) | NLNDPP4OPRD1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930021-A2 | Novel amide derivatives as growth hormone secretagogues | Kaken Pharmaceutical Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7022677-B1 | Amide derivatives as growth hormone secretagogues | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20060014701-A1 | Novel amide derivatives as growth hormone secretagogues | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1158996-A4 | NOVEL AMIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | KAKEN PHARMA CO LTD (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1158996-A1 | NOVEL AMIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | Kaken Pharmaceutical Co., Ltd. (JP) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000048623-A1 | NOVEL AMIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014701-A1 | Novel amide derivatives as growth hormone secretagogues | GHSR, GHRHR, SSTR1 | NLN 3610/4885DPP4 1489/4885MC4R 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.